Lung Cancer Clinical Trials in Georgia

Showing 381-400 of 727 trials

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

NCT05987189

2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.

Lung Cancer

Hummingbird Diagnostics2,000 participantsStarted Oct 2023

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +5 more locations

COMPLETEDPhase 165 miles

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

NCT02897375

This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with treatment. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib with cisplatin or carboplatin may help stop tumor growth in patients with advanced solid tumors.

Solid NeoplasmStage III Pancreatic CancerStage IIIA Breast Cancer+14 more

Emory University71 participantsStarted Oct 2016

Atlanta, Georgia, United States

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Lung Cancer Trials in Other Cities

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

A Study of PRT2527 in Participants With Advanced Solid Tumors

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

The Lung Screening, Tobacco and Health Project

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Survival Prolongation by Rationale Innovative Genomics

International Lung Screen Trial (ILST)

Other Conditions in Georgia